A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets

Francisca F Almeida; Sara Tognarelli; Antoine Marcais; Andrew J Kueh; Miriam E Friede; Yang Liao; Simon N Willis; Kylie Luong; Fabrice Faure; Francois E Mercier; Justine Galluso; Matthew Firth; Emilie Narni-Mancinelli; Bushra Rais; David T Scadden; Francesco Spallotta; Sandra Weil; Ariane Giannattasio; Franziska Kalensee; Tobias Zoeller; Nicholas D Huntington; Ulrike Schleicher; Andreas G Chiocchetti; Sophie Ugolini; Marco J Herold; Wei Shi; Joachim Koch; Alexander Steinle; Eric Vivier; Thierry Walzer; Gabrielle T Belz; Evelyn Ullrich

Journal article

A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets

Francisca F Almeida, Sara Tognarelli, Antoine Marcais, Andrew J Kueh, Miriam E Friede, Yang Liao, Simon N Willis, Kylie Luong, Fabrice Faure, Francois E Mercier, Justine Galluso, Matthew Firth, Emilie Narni-Mancinelli, Bushra Rais, David T Scadden, Francesco Spallotta, Sandra Weil, Ariane Giannattasio, Franziska Kalensee, Tobias Zoeller Show all

OncoImmunology | TAYLOR & FRANCIS INC | Published : 2018

DOI: 10.1080/2162402X.2018.1475875

University of Melbourne Researchers

Yang Liao Author Medical Biology (W.E.H.I.)

Gabrielle Belz Author Medical Biology (W.E.H.I.)

Francisca de Almeida Author Medical Biology (W.E.H.I.)

Andrew Kueh Author Medical Biology (W.E.H.I.)

Marco Herold Author Medical Biology (W.E.H.I.)

Grants

Awarded by National Health and Medical Research Council Australia

Awarded by LOEWE Center for Cell and Gene Therapy Germany

Awarded by European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme

Awarded by ANR

Awarded by fondation ARC

Awarded by European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (TILC)

Awarded by GO-IN post-doc fellowship at the University Frankfurt Germany

Funding Acknowledgements

This work was supported by the National Health and Medical Research Council Australia [1054925]; and the National Health and Medical Research Council Australia [1124907]. E.U. lab has been supported by the LOEWE Center for Cell and Gene Therapy Germany [III L 4-518/17.004]. S.U. lab is supported by funding form the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement No 648768; from the ANR (No ANR-14-CE14-0009-01) and from the fondation ARC (No PGA120140200817). E.V. lab is supported by funding form the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (TILC, grant agreement No 694502); the Agence Nationale de la Recherche; Equipe Labellisee "La Ligue," Ligue Nationale contre le Cancer, MSDAvenir, Innate Pharma and institutional grants to the CIML (INSERM, CNRS, and Aix-Marseille University) and to Marseille Immunopole. S.T. received a GO-IN post-doc fellowship at the University Frankfurt Germany [PCOFUND-GA-2011-291776] and by the Madeleine Schickedanz-KinderKrebs-Stiftung; W.S. is supported by a Walter and Eliza Hall Institute Centenary Fellowship sponsored by CSL Limited. S.N.W. was supported by a Walter and Eliza Hall Trust Centenary Fellowship.